FivePrime scientists are actively searching for new pathways and protein targets in the area of immunology, particularly for indications involving autoimmune and respiratory diseases. Our therapeutic programs address such indications as multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, and respiratory disorders with an immunological component such as asthma, chronic obstructive pulmonary diseases, and pulmonary fibrosis. 

FivePrime’s lead product in immunology is FP-1069, a ligand trap that blocks the activity of IL-34, a master control factor for monocyte cells. Monocyte cells are a class of white blood cells that are active in a number of inflammatory diseases and therefore FP-1069 has potential uses in patients suffering from multiple sclerosis, rheumatoid arthritis and other autoimmune diseases. FivePrime discovered IL-34, a novel cytokine, using its proprietary screen for monocyte survival factors. The receptor for IL-34 was quickly identified using FivePrime’s receptor-ligand matching technology and found to be the receptor for another cytokine, CSF1 (Colony Stimulating Factor 1).  

Preclinical data indicate that FP-1069 may be useful in treating multiple sclerosis, both the relapsing remitting kind as well as the progressive form for which there is currently no therapy. Consequently, FivePrime is collaborating with the Fast Forward  organization, a subsidiary of the National Multiple Sclerosis Society, to accelerate the development of this compound in multiple sclerosis. In addition, our data suggest that FP-1069 has the potential to provide superior relief to rheumatoid arthritis patients not responsive to conventional therapies. FP-1069 is scheduled to enter Phase I clinical trials in 2011.